The FDA has approved a tablet formulation of maralixibat (LIVMARLI) for treating cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.
Researchers found most FDA-authorized COVID-19 treatments were not linked to serious adverse events, though risks may rise with tocilizumab or convalescent plasma in specific patients.
Dexcom G7 15 Day receives FDA clearance, offering adults with diabetes the longest lasting and most accurate continuous glucose monitoring system to date.
"This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use."
The FDA approved nivolumab with ipilimumab for unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer.